oral

PARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment…

IRVING, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) is announcing three partnerships with oral and maxillofacial surgery practices in California and Washington state. They include Whittier Oral and…

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected Depot Standard of…

BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that…

IRVING, Texas, Aug. 17, 2023 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM), the first and largest physician practice management (PPM) company in the oral and maxillofacial surgery specialty, announced today that it has closed…

Announces its Continued Support of OMS Foundation IRVING, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) is proud to announce its continued support of the OMS Foundation, a 501(c) (3) nonprofit that…

Today, while the understanding of moisturizer is topical application like gel, cream or lotion, Skinfay, a leading name in skincare innovation, is proud to announce a groundbreaking shift in the world of moisturization - introducing…

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract…

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6…

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023…